193 related articles for article (PubMed ID: 28558972)
1. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
McGee TD; Yi HA; Allen WJ; Jacobs A; Rizzo RC
Bioorg Med Chem Lett; 2017 Jul; 27(14):3177-3184. PubMed ID: 28558972
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.
Allen WJ; Yi HA; Gochin M; Jacobs A; Rizzo RC
Bioorg Med Chem Lett; 2015 Jul; 25(14):2853-9. PubMed ID: 26013847
[TBL] [Abstract][Full Text] [Related]
3. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
4. Footprint-based identification of viral entry inhibitors targeting HIVgp41.
Holden PM; Kaur H; Goyal R; Gochin M; Rizzo RC
Bioorg Med Chem Lett; 2012 Apr; 22(8):3011-6. PubMed ID: 22425565
[TBL] [Abstract][Full Text] [Related]
5. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
7. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
8. Strategies for lead discovery: application of footprint similarity targeting HIVgp41.
Holden PM; Allen WJ; Gochin M; Rizzo RC
Bioorg Med Chem; 2014 Jan; 22(1):651-61. PubMed ID: 24315195
[TBL] [Abstract][Full Text] [Related]
9. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
11. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
12. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
14. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
Ma X; Tan J; Su M; Li C; Zhang X; Wang C
PLoS One; 2014; 9(11):e111923. PubMed ID: 25393106
[TBL] [Abstract][Full Text] [Related]
16. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
[TBL] [Abstract][Full Text] [Related]
17. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
[TBL] [Abstract][Full Text] [Related]
18. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
Liu S; Wu S; Jiang S
Curr Pharm Des; 2007; 13(2):143-62. PubMed ID: 17269924
[TBL] [Abstract][Full Text] [Related]
19. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
[TBL] [Abstract][Full Text] [Related]
20. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
